Cardiovascular Initiative
凯瑟琳大帝

Addressing cardiovascular health through multidisciplinary research

We aim to improve cardiovascular health for current and future generations across Australia through clinical and translational research.

The Cardiovascular Initiative is a multidisciplinary approach to improving cardiovascular health. It provides common goals for the many unique research and clinical strengths found across the University of Sydney’s staff and affiliates and is built on a cohesive, dynamic and collaborative framework.

The initiative will improve health outcomes for current and future generations by:

translating our research discoveries into practical treatment and care programs
connecting researchers and practitioners from different disciplines to encourage innovation and fresh perspectives on cardiovascular health
providing a collaborative environment between fundamental and clinical researchers that will increase speed and quality of research, enhancing translational research and clinical outcomes for professionals and patients in all areas of cardiovascular care.

六安禄发贵科技有限公司

The Cardiovascular Initiative provides a strategic interface between our fundamental cardiovascular research and the translational and clinical work of Sydney Health Partners, with support from the University of Sydney’s Research Portfolio and Charles Perkins Centre.

Our strong connections with Sydney Health Partners mean we are uniquely placed to capitalise on the leading research already carried out at the University, increasing awareness and capacity for multidisciplinary collaboration, building a sense of community, and enhancing the ‘bench to bedside’ translational focus of research.

商丘盈中晶科技有限公司

We are focused on three multidisciplinary research pipelines:

Cardiovascular Precision Medicine 商州万宏利商贸有限公司

We will be working with experts in precision medicine and translational bioinformatics to facilitate biomarker discovery, development and application in cardiovascular disease using the well-phenotyped cohorts of Sydney Health Partners and its members. This will maximise the opportunities we have from our genomics, transcriptomics and proteomics research teams, as well as more candidate-focused work in vascular inflammation and redox signaling.

Our ultimate goals include discovery of new mechanisms and therapeutic targets for disease, as well as new biomarkers for early risk identification and stratification, thus facilitating improved precision in preventative strategies.

Cardiovascular Drug Discovery 安阳干瑞同有限公司

Our drug discovery pipeline brings together the expertise of fundamental chemists in drug discovery and small molecule design, with cellular and preclinical models of cardiovascular disease. Working with Sydney Health Partners and using our clinical trials expertise, we will have a keen eye on translation to early phase clinical trials. This will capitalise on the depth of fundamental vascular and myocardial biology embedded in our clinical departments.

Cardiovascular Bioengineering 邢台生宏升科技有限公司

The Cardiovascular Initiative will bring our experts in bioengineering, physics and mathematics closer to understanding current cardiovascular problems. Early challenges identified are: tissue engineering (including bioprinting, stem cell work, hydrogel composition, and biomaterials); devices (including percutaneous valves, pacemaker, defibrillators); and fluid dynamics (4D flow cardiovascular MRI; intracoronary flow measures; CT coronary angiography and modelling of flow and shear).

许昌德弘厚机械有限公司

The Cardiovascular Initiative is supported by its team, members and partners who are committed to the aim of improving cardiovascular health outcomes across Australia through clinical and translational research.

贵阳辉飞厚服务有限公司

Professor Gemma Figtree

湖南省禄元东有限公司

Vicki Snelson

Vicki has a commercial health research and rapid diagnostics development background with experience working in start-up companies and large pharma. She has developed new products, assisted in the implementation of ISO and TGA accredited manufacturing processes, and has been involved in development of channel partnerships and technology transfer.

玉林汇隆永科技有限公司

Precision Medicine – Dr John O’Sullivan and Dr Mark Larance

Drug Discovery – Dr Belinda Di Bartolo

Bioengineering Lead - Professor Alistair McEwan and Associate Professor James Chong

Early and Mid Career Researcher Lead - Dr Anusha Withana

安庆捷成汇机械有限公司

The initiative currently has over 300 members. If you would like to become a member please email Vicki Snelson at cardiovascular.initiative@sydney.edu.au

和田高发泰服务有限公司

涟源春新伟商贸有限公司

With your help, our interdisciplinary research can transform the lives of individuals and families affected by cardiovascular disease, throughout Australia and around the world.

Your gift to the University of Sydney’s Cardiovascular Initiative will help us to build a brighter and healthier future for many by supporting the impactful work we are doing.

To find out more about ways to give please contact Sallie May, sallie.may@sydney.edu.au.